Press Releases

Breadcrumb

Investors // Press Releases //

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Novelion Therapeutics Announces New Trading Symbol
VANCOUVER, British Columbia and CAMBRIDGE, Mass., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (Ticker: NVLNF) (“Novelion” or the “Company”) announced that, effective as of the opening of business today, its common shares have commenced trading under the symbol “NVLNF” on an
View HTML
Toggle Summary Novelion Therapeutics Announces Nasdaq Delisting
VANCOUVER, British Columbia , and CAMBRIDGE, Mass. , Oct. 08, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN) (“Novelion” or the “Company”), announced that on October 7, 2019 the Nasdaq Office of General Counsel notified the Company that the Nasdaq Hearing Panel (the “Panel”) has
View HTML
Toggle Summary Novelion Therapeutics Announces Filing of Definitive Proxy Statement in Connection with Proposed Liquidation and Other Matters
VANCOUVER, British Columbia , and CAMBRIDGE, Mass. , Oct. 03, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN) (“Novelion” or the “Company”) today announced that it has filed its notice of meeting and definitive proxy statement with the applicable securities regulatory authorities
View HTML
Toggle Summary Novelion Therapeutics Announces Completion of Aegerion Transaction and Departure of Certain Directors and Officers
VANCOUVER, British Columbia and CAMBRIDGE, Mass. , Sept. 25, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN) (“Novelion” or the “Company”), announced that, further to its press release dated September 11, 2019 , the acquisition by Amryt Pharma Plc (“Amryt”) of 100% of the
View HTML
Toggle Summary Novelion Therapeutics Announces US Court Confirmation of Aegerion Bankruptcy Case, Update on Nasdaq Delisting and Date of Annual General Meeting of Shareholders
VANCOUVER, British Columbia , and CAMBRIDGE, Mass. , Sept. 11, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN) (“Novelion” or the “Company”), announced that, further to its press release dated August 30, 2019 , the United States Bankruptcy Court for the Southern District of New
View HTML
Toggle Summary Novelion Therapeutics Provides Update Regarding Delisting from Nasdaq and Aegerion Bankruptcy Case
VANCOUVER, British Columbia and CAMBRIDGE, Mass. , Aug. 30, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN) (“Novelion” or the “Company”), announced that, further to its press release dated August 21, 2019 , it has received a notice from the Nasdaq Hearings Panel (the “Panel”)
View HTML
Toggle Summary Novelion Therapeutics Announces Issuance of General Cease Trade Order in Canada and Notice of Delisting from Nasdaq
VANCOUVER, British Columbia and CAMBRIDGE, Mass. , Aug. 21, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN) (“Novelion” or the “Company”) announced that, further to its press release dated August 12, 2019 , the British Columbia Securities Commission and the Ontario Securities
View HTML
Toggle Summary Novelion Therapeutics Announces Anticipated Late Filing of Quarterly Report on Form 10-Q for the Quarter Ended June 30, 2019
VANCOUVER, British Columbia and CAMBRIDGE, Mass. , Aug. 12, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases (“Novelion” or the “Company”), announced that it has
View HTML
Toggle Summary Novelion Therapeutics Announces Dismissal of Whitefort Capital Petition
VANCOUVER, British Columbia , July 16, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc.  (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases (“Novelion”), announced that on July 16, 2019 , the Supreme Court
View HTML
Toggle Summary Novelion Therapeutics Receives Delisting Notifications
VANCOUVER, British Columbia , July 05, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc.  (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases, announced that on July 3, 2019 , the Company received a written
View HTML